AstraZeneca Discontinues PPAR Candidate Galida
This article was originally published in The Pink Sheet Daily
Executive Summary
Safety issues have plagued development of the diabetes treatment class.
You may also be interested in...
AstraZeneca Turns Gaze On Global Impact Of Diabetes Crisis
HONG KONG - If viral diseases were the scourge of the nineteenth and twentieth centuries, diseases born of more effective healthcare and wealth might represent the next threat. Prominent among them is diabetes, which causes about 5 percent of deaths around the world every year
Bristol Aims To Be First To Market With Novel Diabetes Drug Class
Bristol and AstraZeneca ink deal potentially worth over $1 billion to develop Bristol’s prospective first-in-class SGLT-2 inhibitor and DPP-4 candidate saxagliptin.
Bristol Aims To Be First To Market With Novel Diabetes Drug Class
Bristol and AstraZeneca ink deal potentially worth over $1 billion to develop Bristol’s prospective first-in-class SGLT-2 inhibitor and DPP-4 candidate saxagliptin.